Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
Dec 19, 2023
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer. “In 2020 ASCO recommended that all women with epithelial ovarian cancer have germline testing for BRCA1/2 mutations, and those without a germline pathogenic variant should have somatic tumor testing, to determine eligibility for PARP inhibitor therapy,” wrote Janice S. Kwon, University of British Columbia, Vancouver, BC, Canada, and colleagues. “An alternate strategy is to start with tumor testing first, and to conduct germline testing only in those with a pathogenic variant in the tumor, or a significant family history,” they continued.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…